Randomized Phase 2 Study of VE303 for Prevention of Recurrent Clostridium Difficile Infection (CONSORTIUM)

Brief description of study

CONSORTIUM is a randomized, double-blind phase 2 study to evaluate safety, tolerability, PK/PD, and efficacy of VE303 in adult subjects with 1 or more recurrences of Clostridium difficile infection (CDI), including the current episode. VE303 or placebo capsules will be taken orally for 14 days after completion of a course of standard of care antibiotics. The proportion of subjects experiencing a confirmed CDI recurrence, within 8 weeks after the first dose of study treatment, will be compared across the study arms to understand the effectiveness of VE303 in preventing subsequent rCDI. Approximately 146 subjects with: a history of CDI, diarrhea, a positive C. difficile toxin stool sample test, and who have responded to standard-of-care (SOC) antibiotic treatment, will be enrolled in the study. Participants will be randomly assigned, in a 1:1:1 ratio to 1 of 3 treatment arms (VE303 high dose, VE303 low dose, and placebo). Participants and their doctors will not know which treatment arm is assigned.


Clinical Study Identifier: s19-00505
Principal Investigator: Jordan E Axelrad.


If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.